Trial Profile
A Phase I, Double-blind, Placebo-controlled, Ascending Single-dose, Safety, Tolerability and Pharmacokinetic Study of QGC001 in Healthy Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Firibastat (Primary)
- Indications Hypertension
- Focus Adverse reactions; First in man
- Sponsors Quantum Genomics
- 18 Jul 2013 New source identified and integrated: ClincalTrials.gov record.
- 19 Oct 2012 Status changed from recruiting to completed, as reported in a Quantum Genomics media release.
- 13 Apr 2012 Status changed from not yet recruiting to recruiting, as repored in a Quantum Genomics media releasel